Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan

Saved in:
Bibliographic Details
Published inHuman Vaccines & Immunotherapeutics Vol. 19
Main Authors Junko Terada-Hirashima, Yuki Takamatsu, Yosuke Shimizu, Yukari Uemura, Junko S. Takeuchi, Noriko Tomita, Kouki Matsuda, Kenji Maeda, Shohei Yamamoto, Ami Fukunaga, Norio Ohmagari, Ayako Mikami, Kengo Sonoda, Mugen Ujiie, Hiroaki Mitsuya, Wataru Sugiura
Format Journal Article
LanguageJapanese
Published Informa UK Limited 02.01.2023
Subjects
Adult
adverse events
Antibodies, Neutralizing
Antibodies, Viral
BNT162 Vaccine
Coronavirus
COVID-19
covid-19 vaccine
COVID-19 Vaccines
Humans
Immunogenicity, Vaccine
Immunologic diseases. Allergy
inactivated vaccine
Japan
kd-414
neutralizing antibody
RC581-607
RM1-950
SARS-CoV-2
side effects
Therapeutics. Pharmacology
vaccine safety
Online AccessGet full text

Cover

More Information
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2023.2193074